Eli Lilly draws the line on DTC

Share this article:
Eli Lilly is drawing the line on DTC—at the spots plugging the services of ambulance-chasing trial lawyers. The company surveyed 402 shrinks and found that ads by would-be litigators warning of side effects in anti-psychotics are scaring patients off the drugs.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Pharmaceutical

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.